OBJECTIVE: We sought to define the prognostic significance of histologic subtype for extremity/truncal liposarcoma (LPS). BACKGROUND: LPS, the most common sarcoma, is comprised of 5 histologic subtypes. Despite their distinct behaviors, LPS outcomes are frequently reported as a single entity. METHODS: We analyzed data on all patients from a single-institution prospective database treated from July 1982 to September 2017 for primary, nonmetastatic, extremity or truncal LPS of known subtype. Clinicopathologic variables were tested using competing risk analyses for association with disease-specific death (DSD), distant recurrence (DR), and local recurrence (LR). RESULTS: Among 1001 patients, median follow-up in survivors was 5.4 years. Tumor size and subtype were independently associated with DSD and DR. Size, subtype, and R1 resection were independently associated with LR. DR was most frequent among pleomorphic and round cell LPS; the former recurred early (43% by 3 years), and the latter over a longer period (23%, 3 years; 37%, 10 years). LR was most common in dedifferentiated LPS, in which it occurred early (24%, 3 years; 33%, 5 years), followed by pleomorphic LPS (18%, 3 years; 25%, 10 years). CONCLUSIONS: Histologic subtype is the factor most strongly associated with DSD, DR, and LR in extremity/truncal LPS. Both risk and timing of adverse outcomes vary by subtype. These data may guide selective use of systemic therapy for patients with round cell and pleomorphic LPS, which carry a high risk of DR, and radiotherapy for LPS subtypes at high risk of LR when treated with surgery alone.
OBJECTIVE: We sought to define the prognostic significance of histologic subtype for extremity/truncal liposarcoma (LPS). BACKGROUND: LPS, the most common sarcoma, is comprised of 5 histologic subtypes. Despite their distinct behaviors, LPS outcomes are frequently reported as a single entity. METHODS: We analyzed data on all patients from a single-institution prospective database treated from July 1982 to September 2017 for primary, nonmetastatic, extremity or truncal LPS of known subtype. Clinicopathologic variables were tested using competing risk analyses for association with disease-specific death (DSD), distant recurrence (DR), and local recurrence (LR). RESULTS: Among 1001 patients, median follow-up in survivors was 5.4 years. Tumor size and subtype were independently associated with DSD and DR. Size, subtype, and R1 resection were independently associated with LR. DR was most frequent among pleomorphic and round cell LPS; the former recurred early (43% by 3 years), and the latter over a longer period (23%, 3 years; 37%, 10 years). LR was most common in dedifferentiated LPS, in which it occurred early (24%, 3 years; 33%, 5 years), followed by pleomorphic LPS (18%, 3 years; 25%, 10 years). CONCLUSIONS: Histologic subtype is the factor most strongly associated with DSD, DR, and LR in extremity/truncal LPS. Both risk and timing of adverse outcomes vary by subtype. These data may guide selective use of systemic therapy for patients with round cell and pleomorphic LPS, which carry a high risk of DR, and radiotherapy for LPS subtypes at high risk of LR when treated with surgery alone.
Authors: Joseph H Schwab; Patrick Boland; Tianhua Guo; Murray F Brennan; Samuel Singer; John H Healey; Cristina R Antonescu Journal: Ann Surg Oncol Date: 2007-01-26 Impact factor: 5.344
Authors: A Italiano; M Toulmonde; A Cioffi; N Penel; N Isambert; E Bompas; F Duffaud; A Patrikidou; B Lortal; A Le Cesne; J-Y Blay; R G Maki; G K Schwartz; C R Antonescu; S Singer; J-M Coindre; B Bui Journal: Ann Oncol Date: 2011-10-29 Impact factor: 32.976
Authors: Alessandro Gronchi; Dirk C Strauss; Rosalba Miceli; Sylvie Bonvalot; Carol J Swallow; Peter Hohenberger; Frits Van Coevorden; Piotr Rutkowski; Dario Callegaro; Andrew J Hayes; Charles Honoré; Mark Fairweather; Amanda Cannell; Jens Jakob; Rick L Haas; Milena Szacht; Marco Fiore; Paolo G Casali; Raphael E Pollock; Chandrajit P Raut Journal: Ann Surg Date: 2016-05 Impact factor: 12.969
Authors: Kimberly Moore Dalal; Michael W Kattan; Cristina R Antonescu; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2006-09 Impact factor: 12.969
Authors: Jordi Barretina; Barry S Taylor; Shantanu Banerji; Alexis H Ramos; Mariana Lagos-Quintana; Penelope L Decarolis; Kinjal Shah; Nicholas D Socci; Barbara A Weir; Alan Ho; Derek Y Chiang; Boris Reva; Craig H Mermel; Gad Getz; Yevgenyi Antipin; Rameen Beroukhim; John E Major; Charles Hatton; Richard Nicoletti; Megan Hanna; Ted Sharpe; Tim J Fennell; Kristian Cibulskis; Robert C Onofrio; Tsuyoshi Saito; Neerav Shukla; Christopher Lau; Sven Nelander; Serena J Silver; Carrie Sougnez; Agnes Viale; Wendy Winckler; Robert G Maki; Levi A Garraway; Alex Lash; Heidi Greulich; David E Root; William R Sellers; Gary K Schwartz; Cristina R Antonescu; Eric S Lander; Harold E Varmus; Marc Ladanyi; Chris Sander; Matthew Meyerson; Samuel Singer Journal: Nat Genet Date: 2010-07-04 Impact factor: 38.330
Authors: Penella J Woll; Peter Reichardt; Axel Le Cesne; Sylvie Bonvalot; Alberto Azzarelli; Harald J Hoekstra; Michael Leahy; Frits Van Coevorden; Jaap Verweij; Pancras C W Hogendoorn; Monia Ouali; Sandrine Marreaud; Vivien H C Bramwell; Peter Hohenberger Journal: Lancet Oncol Date: 2012-09-04 Impact factor: 41.316